CIK 0001671858 · Non-accelerated filer<br>Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811489190
- Phone
- 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-02 | Chakma Justin Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −45,000 | 3,260 | ||
| 2024-12-02 | Shawver Laura Director | Option exercise 10b5-1 | +67,616 | $1.27 | $86K | 277,962 |
| 2024-12-02 | Shawver Laura Director | Option exercise 10b5-1 | +29,628 | $1.27 | $38K | 307,590 |
| 2024-12-02 | Shawver Laura Director | Sale 10b5-1 | −96,343 | $13.55 | $1.3M | 211,247 |
| 2024-12-02 | Shawver Laura Director | Sale 10b5-1 | −901 | $14.34 | $13K | 210,346 |
| 2024-12-02 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −29,628 | 25,606 | ||
| 2024-12-02 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −67,616 | 0 | ||
| 2024-12-02 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 | +3,717 | $1.50 | $6K | 9,410 |
| 2024-12-02 | Karas Eric Chief Commercial Officer | Sale 10b5-1 | −3,717 | $14.11 | $52K | 5,693 |
| 2024-12-02 | Karas Eric Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,717 | 590,871 | ||
| 2024-11-27 | Chakma Justin Chief Business Officer | Sale | −25,000 | $14.39 | $360K | 136,380 |
| 2024-11-26 | Chakma Justin Chief Business Officer | Sale | −42,186 | $14.05 | $593K | 161,380 |
| 2024-11-25 | Chakma Justin Chief Business Officer | Sale | −32,814 | $14.00 | $459K | 203,566 |
| 2024-11-19 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −50,000 | $13.95 | $698K | 1,347,447 |
| 2024-11-19 | Lowenthal Richard E PRESIDENT AND CEO | Sale 10b5-1 | −50,000 | $13.95 | $697K | 1,198,499 |
| 2024-11-19 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −50,000 | $13.95 | $698K | 1,347,447 |
| 2024-11-19 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −50,000 | $13.95 | $697K | 1,198,499 |
| 2024-11-12 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −45,045 | $16.76 | $755K | 1,301,449 |
| 2024-11-12 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −4,955 | $17.64 | $87K | 1,296,494 |
| 2024-11-12 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −45,124 | $16.76 | $756K | 1,253,375 |
Page 9 of 14 · 267 trades